{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:27Z","timestamp":1790364207805,"version":"4.1.0"},"reference-count":13,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Prediabetes is a serious and major global problem afflicting approximately 21% of the world\u2019s population. It is the intermediate stage between normal glucose levels and type 2 diabetes mellitus (T2DM). Prediabetes is associated with major complications including the development of T2DM and increased cardiovascular disease (CVD). It can be easily diagnosed with an inexpensive plasma glucose level and\/or a hemoglobin A1c (HbA1c) measurement. The mainstay of treatment is intensive lifestyle (ILS) intervention, including reduction in calories, especially saturated fats, refined carbohydrates, etc., coupled with regular physical activity of 150 min per week since ILS changes, with at least a 5% weight loss, have been shown to reduce progression to T2DM in multiple studies globally. Also, metformin therapy has been shown to prevent the progression to T2DM. In conclusion, serious consideration by guideline committees to classify prediabetes as a disease is highly recommended based on its global burden, easy and cost-effective diagnosis, association with serious conditions of diabetes and CVD, and effective ILS intervention. Therapy targeting those at an especially high risk for T2DM, such as persons with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) with values \u2265 110 mg\/dL (6.1 mmol\/L), and\/or HbA1c \u2265 6.0% (42 mmol\/mol) coupled with overweightness or obesity.<\/jats:p>","DOI":"10.3390\/jcm15020710","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:31:41Z","timestamp":1768480301000},"page":"710","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Should Prediabetes Be Classified as a Treatable Disease?"],"prefix":"10.3390","volume":"15","author":[{"given":"William E.","family":"Winter","sequence":"first","affiliation":[{"name":"Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9113-2604","authenticated-orcid":false,"given":"Ishwarlal","family":"Jialal","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pathology, UC Davis School of Medicine, 2616 Hepworth Drive, Davis, CA 95618, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41572-025-00635-0","article-title":"Prediabetes","volume":"11","author":"Unnikrishnan","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The Lancet Diabetes Endocrinology (2025). Prediabetes: Much more than just a risk factor. Lancet Diabetes Endocrinol., 13, 165.","DOI":"10.1016\/S2213-8587(25)00034-8"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S27\u2013S49.","DOI":"10.2337\/dc26-S002"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jama.2023.4063","article-title":"Diagnosis and Management of Prediabetes: A Review","volume":"329","author":"Perreault","year":"2023","journal-title":"JAMA"},{"key":"ref_5","first-page":"1","article-title":"A Review of Prediabetes: Diagnosis, Consequences and Interventions","volume":"1","author":"Olatunbosun","year":"2025","journal-title":"Int. J. Clin. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111589","DOI":"10.1016\/j.diabres.2024.111589","article-title":"International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes","volume":"209","author":"Bergman","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117313","DOI":"10.1016\/j.atherosclerosis.2023.117313","article-title":"Lipid-lowering in diabetes: An update","volume":"394","author":"Chait","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-024-06315-0","article-title":"Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes","volume":"68","author":"Rooney","year":"2025","journal-title":"Diabetologia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-8587(25)00022-1","article-title":"Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial","volume":"13","author":"Knowler","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2337\/dc25-0014","article-title":"The Diabetes Prevention Program and Its Outcomes Study: NIDDK\u2019s Journey into the Prevention of Type 2 Diabetes and Its Public Health Impact","volume":"48","author":"Crandall","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S50\u2013S60.","DOI":"10.2337\/dc26-S003"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2213-8587(25)00295-5","article-title":"Prediabetes remission and cardiovascular morbidity and mortality: Post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study","volume":"14","author":"Gong","year":"2026","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/710\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:28:34Z","timestamp":1768483714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020710"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020710","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}